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The effects of lactic acid bacteria-fermented soybean extract (Biofermentics
TM; BF) on
experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat,
hepatitis induced by feeding of deoxycholic acid (DCA, 0.5wt/wt, n=6) or intraperitoneal
injection of D-galactosamine (GMN, 500mg/body wt, n=6), the increase in serum AST
(aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited
significantly (P<0.05) by feeding a diet containing 5% dried BF. Moreover, the
BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger
amount of urine as compared with values in the control group. Pretreatment of primary cell
cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K2Cr2O7)
resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of
lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by
malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These
results suggest that BF may play a role in hepatic and renal disorders, and may be useful for
maintaining health in humans as well.
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Introduction
It is now a world-wide trend to incorporate dietary
supplements into comprehensive medicine (1), and
evidence-based medicine (EBM) (2,3), which is required
for the recognition and acceptance of these supplements.
It has become widely recognized that soybeans contain
beneficial components for human health, such as soy
protein, peptides, oligosaccharides, phospholipids, isofla-
vones, saponins, minerals and vitamins (4). The fermen-
tation of soybeans results in various compositional and
functional changes, and a large variety of peptides and
amino acids are produced from soy protein by different
kinds of micro-organisms, which include lactic acid
bacteria. Aglycones from isoflavone or saponin gluco-
sides are released by b-glucosidase of fungi and lactic
acid bacteria (5,6). The aglycon form of isoflavones and
saponins has a higher absorptivity than the glycoside
form in humans (7).
There are many traditional soybean products fermented
by micro-organisms, particularly in the eastern Asian
countries, such as soy sauce (lactobacilli and yeasts) (8),
‘natto’(Bacillussubtilisnatto)(9)andtempeh(Rhizopussp.)
(10). These products are fermented mostly by mold,
yeast, bacteria or a combination of these micro-
organisms. However, there have been few products
fermented exclusively by lactic acid bacteria except a few
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properly cited.recent soymilk products, fermented mostly by
the inoculation of a single pure culture of bifidobacteria
(11) or lactic acid bacteria (12) as probiotic food.
The purpose of this study was to evaluate the effects of
a new dietary supplement, Biofermentics
TM (BF), which
consists of soybean fermented by a combination of
different species of lactic acid bacteria and yeasts, on
in vitro and in vivo hepatic and renal disorder models
in rats.
Methods
Preparation of Lactic Acid Bacteria-fermented Soybean
Extract (Biofermentics
TM; BF)
Soymilk was prepared from soybeans of the ‘Tsurunoko’
variety, grown with less agricultural chemicals, in
Hokkaido, the northern part of Japan. The soybeans
were soaked in water, ground, heated to 98C for 30min
and expressed through linen. The filtrate was used as
soymilk. For fermentation of the soymilk, 12 frozen stock
strains of lactic acid bacteria, such as Lactobacillus
plantarum, L. casei, L. reuteri and Lactococcus lactis
and four strains of the yeast Saccharomyces cerevisiae,
were used. Together, the strains were divided into four
groups of seed cultures A, B, C and D. Each group
consisted of two strains of Lactobacillus, one strain of
Lactococcus and one strain of S. cerevisiae. For prepara-
tion of the seed cultures, each group of frozen stock was
inoculated into the appropriate amount of soymilk and
incubated at 37C for 2 days.
The inoculum sizes were adjusted to 110
5ml
1 and
110
4ml
1 for the lactic acid bacteria and yeast,
respectively, based on the predetermined cell numbers
in the frozen stock cultures. The four seed cultures were
then mixed together, inoculated into a large volume of
fresh soymilk of approximately 100 times of the
inoculum, and incubated at 37C for 4 days. The large
bulk of fermented soymilk was heated to 98C for 30min,
cooled to room temperature and extracted by the
addition of ethyl alcohol at a final concentration of
14%v/v for about 2 weeks. Then, the extract was
separated through filter paper. Both the filtrate and
precipitate were used for the different products of
lactic acid bacteria-fermented soybean extract
(Biofermentics; BF). They were usually freeze-dried.
Rats
Male Wistar rats of 5 weeks of age were purchased from
Charles River Co., Tokyo and pre-bred with MF
powdery feed (Oriental Yeast Co., Ltd., Tokyo) for a
week in a breeding room with a temperature of 231C,
humidity of 505% and photoperiod cycle of 12h
light/12h dark.
The care and treatment of rats were done in accordance
with the guidelines of institutional animal ethics pre-
scribed by the guidelines of Science Council of Japan for
the care and use of laboratory animals.
Oral Administration of BF on Deoxycholic Acid
(DCA)-Induced Hepatic and Renal Disorders
At 6 weeks old, the rats were divided into two groups
(experimental and control) of 6 rats each, such that the
mean and variation of body weights between the two
groups were virtually identical. The control group was
given MF feed containing exclusively 0.5% DCA
(Wako Pure Chemical Industries, Ltd., Osaka) for 6
weeks, while the experimental group was given MF
powdery feed containing both 5% BF and 0.5% DCA.
Both feed and drinking water were given ad libitum.
Blood was collected from the tail vein of each rat at a
volume of 0.5ml at 0, 2, 4 and 6 weeks after the start of
the feeding experiment and separated from serum.
The concentration of L-asparate aminotransferase
(AST), L-alanine aminotransferase (ALT), blood urea
nitrogen (BUN), uric acid (UA) and total cholesterol
(T-CHL) in the serum were measured using an enzymic
test kit (C-test, Wako; Wako pure Chemical Industries,
Ltd., Osaka).
During the final week of the experimental period, each
rat was housed in a metabolic cage to measure the daily
urine amount excreted and concentrations of electrolytes in
the urine. The rats were finally anesthetized in a CO2 bag,
their blood immediately collected from the abdominal large
vein using a syringe and organs weighed. The collected
serum was used to determine the concentrations of total
protein (TP), alkali phosphatase (ALP), g-glutamyl trans-
peptidase (g-GTP), leucine aminopeptidase (LAP) and
glucose (GLU) using multilayer film analytical element,
dri-chem colorimetric analyzer 3030 (Fuji Photo Film Co.,
Ltd., Tokyo), and the concentrations of lipid peroxide
(LPO), b-lipoprotein (b-LP) and total bile acid (T-BA)
were determined using an enzymic test kit (C-test, Wako;
Wako pure Chemical Industries, Ltd., Osaka).
Oral Administration of BF on D-Galactosamine
(GMN)-Induced Hepatic Disorders
Male Wistar rats of 6 weeks were divided into two groups
of similar mean and variation of body weight. One group
used as control (n=7) was given MF feed only, while the
BF group (n=6) was given MF feed containing 5% BF.
Both feed and drinking water were given ad libitum for
3 weeks. At the beginning of the final week of
experimental period, all rats were intraperitoneally
injected once with a GMN- (Wako Pure Chemical
Industries, Ltd., Osaka) solution in a dosage of
500mgkg
1 body wt. Blood was collected from the tail
vein in a volume of 0.5ml, and serum AST activity was
358 Function of fermented soybean extractmeasured on days 1, 2, 3 and 6 following GMN
administration.
Estimation of Cytotoxicity
Cytotoxicity caused by exposure to dichromate
(K2Cr2O7; Kanto Chemical Co., Tokyo) was estimated
by measuring the concentration of lactate dehydrogenase
(LDH) leaked from primary cultures of rat hepatocytes
and nephrocytes as previously described (13–16). In brief,
approximately 210
6 collagenase-dispersed (Wako pure
Chemical Industries, Ltd., Osaka) rat hepatocytes in
medium E were plated onto 60-mm diameter Corning
Petri dishes (Iwaki Glass, Ltd., Chiba, Japan) and
incubated in a humidified atmosphere of 5% CO2 and
95% air at 37C for 3h. Following that, BF was added to
the primary culture media at 1.3, 2.5, 5.0 or 10mlml
1
and incubated further for 20h. The medium was then
discarded and the primary cell sheets were overlaid with
salt-glucose medium {SGM: 50mM 4-(2-hydroxyethyl)
-1-piperazinesulfonic acid buffer (pH 7.2) with 100mM
NaCl, 5mM KCl, 2mM CaCl and 5mM glucose}
containing dichromate (1mM) and BF at the above
three concentrations and incubated at 37C for 8h. The
SGM from Petri dishes was centrifuged at 1000rpm at
4C for 5min to remove cell debris, and the supernatant
was examined for LDH released from cells by the method
described by Mitchell et al. (17).
The control primary cultures, without any exposure to
BF or dichromate, were frozen with SGM and thawed.
This freeze-thaw procedure was repeated three times.
Then, cell sheets were scraped off with a rubber spatula,
sonicated with a Handy Sonic model UR-20P (Tomy
Seiko Co., Ltd., Tokyo) by pulsing for 1min at an
intensity of 8, and then centrifuged at 10000r.p.m at 4C
for 10min. The supernatant was subjected to analysis of
total LDH in the control hepatocytes. The percent of
LDH released from cells treated with BF and dichromate
was calculated against the total LDH from the control
hepatocytes. The effect of BF on dichromate-induced
cytotoxicity of primary cultures of rat nephrocytes was
evaluated in a similar way as hepatocytes. The percentage
of LDH leakage from nephrocytes was estimated as the
ratio of LDH released in SGM from BF-treated cells to
that from non BF-treated cells.
Assay for Lipid Peroxidation
Since dichromate compounds have been shown to
facilitate malondialdehyde (MDA) formation through
lipid peroxidation in isolated hepatocytes (18), the effect
of BF on MDA formation was examined using primary
cultures of rat hepatocytes, as previously described (19).
In brief, following treatment with dichromate as men-
tioned in the foregoing section, the cells were washed
twice with ice-cold phosphate-buffered saline (PBS) and
dislodged from dishes by scraping. The cells were
re-suspended in ice-cold PBS and sonicated, and the
sonicate was used for the estimation of cellular levels of
lipid peroxidation by monitoring MDA formation (20).
Statistical Analysis
The differences between the mean values of the data were
evaluated by the Student’s t-test for equal variance or
Welch’s t-test for unequal variance. A P-value of less
than 0.05 was considered to be statistically significant.
Because of the skewed distribution of AST or ALT in rat
experiments, data were normalized by logarithmic trans-
formation for further statistical analysis. However, no
transformed values were presented in the ‘results’ section.
Results
Improvement of DCA-induced Hepatic and Renal
Disorders
As shown in Fig. 1A, in the DCA-administered control
group, serum AST activity rapidly increased to 786475
IUl at 2 weeks, reached its highest value of
24692182IU/l at 4 weeks, then sharply decreased to
722502IU/l at 6 weeks. However, these rapidly
increased activities were markedly lowered to
195105IU/l, 788744IU/l and 14767IU/l at 2,
4 and 6 weeks, respectively, in the BF- and DCA-
administered group. Thus, the increase of AST activity
induced by DCA was clearly reduced by the administra-
tion of BF, with reductions significant (P<0.05) at
2 and 6 weeks. Similarly, in the case of ALT, the
increased activity found in controls was also depressed in
the BF- administered group (Fig. 1B), with the value at
2 weeks significantly different (P<0.05) from the DCA-
administered control group.
As seen in Table 1, rats in the BF and DCA group
showed significantly (P<0.01) lower serum BUN values
at 4 and 6 weeks, as compared with control groups.
No significant effects were observed in UA and T-CHL
values following BF administration. As for the biochem-
ical analysis of the serum, no clear change between
control and BF groups was observed for TP, ALP,
g-GTP, LAP, GLU, LPO and b-LP (Table 2). However,
the concentration of T-BA in the serum of the control
group (8136nmolml
1) was considerably different
from that of BF group (4634nmolml
1). Thus, the
BF-administered group tended to show lower concentra-
tions of total bile acid than the control group. Although
the amount of urine was found to be larger in the
BF group than in the control group, there were no
significant differences in urine electrolyte (Na, K and Cl)
concentrations.
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As shown in Fig. 2, serum AST activity in the control
group increased sharply to 31722379IU/l on day 1 and
28112210IU/l on day 2, then decreased sharply to
372323IU/l on day 3 after injection of GMN. In the
BF group, AST was significantly (P<0.05) lowered to
14231857, 10091395 and 142161IU/l on those
days, respectively, that is, to 45% the level of values in
the control group.
Cytotoxicity
As shown in Fig. 3, when the hepatocytes were treated
with 1mM dichromate, they were damaged and leaked
LDH at a level of 18% of total LDH in normal cells.
However, when they were treated with dichromate and
BF at the same time, the LDH leakage was significantly
inhibited to a level of 7.0% of untreated control cells,
indicating that BF treatment had a protective effect
against cytotoxicity caused by dichromate treatment.
No adverse effects were observed with BF treatment in
the range of concentrations employed.
Figure 4 shows that the treatment of nephrocytes with
BF at a concentration of more than 2.5mlml
1 for 16h
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Figure 1. Effects of oral BF administration on serum AST (A) and ALT
(B) activities in rats with hepatic disorders induced by DCA loading.
The DCA control group (open square) was given MF powdery feed
containing 0.5% DCA only while the DCA and BF group (filled circle)
was given MF powdery feed containing both 0.5% DCA and 5% BF.
Values indicate meanSD (n=6). *P<0.05 against the respective
control values. BF, Biofermentics
TM(lactic acid bacteria-fermented
soybean extract); AST, L-asparate aminotransferase; ALT, L-alanine
aminotransferase; DCA, deoxycholic acid (hepatopathy inducer).
Table 1. Biochemical analysis of the serum from DCA-only and DCA- and BF-administered rats
Analytical items Groups Administration period (weeks)
024 6
BUN (mg/dl) DCA-administered 27.82.3 28.07.9 27.13.0 25.02.5
DCA- and BF- administered 26.21.2 25.64.8 21.92.2* 19.81.1*
UA (mg/dl) DCA-administered 2.20.6 2.40.4 2.00.5 2.30.6
DCA- and BF- administered 2.20.5 2.40.7 1.70.5 2.20.5
T-CHL (mg/dl) DCA-administered 6911 12128 16265 11812
DCA- and BF- administered 7811 12217 12912 12716
*P<0.05 compared to the corresponding value of the DCA administered group.
BF, Biofermentics
TM (lactic acid bacteria-fermented soybean extract); BUN, blood urea nitrogen; UA, uric acid; T-CHL, total cholesterol;
DCA, deoxycholic acid.
Table 2. Biochemical analysis of the serum from DCA-only and
DCA-and BF-administered rats
Analytical items DCA-
administered
group
DCA-and
BF-administered
group
Serum Total protein (g/dl) 7.00.3 7.40.3
Alkali phosphatase (IU/l) 694143 635127
g-Glutamyl transpeptidase (IU/l) 5.01.7 5.21.8
Leucine aminopeptidase (U) 397199 363156
Glucose (mg/dl) 15655 17225
Lipid peroxide (nmol/ml) 2.32.4 1.71.4
b-Lipoprotein (mg/dl) 4732 5334
Total bile acids (nmol/ml) 8136 4634
Urine Urine excretion (ml/day) 2114 3010
Urine/water intake (%) 5676 9 18
Urinary electrolyte
(mEq/day): Na
1.40.7 2.11.1
K 2.91.3 4.62.2
Cl 1.70.8 2.71.7
DCA, deoxycholic acid; BF, Biofermentics
TM (lactic acid bacteria-
fermented soybean extract).
360 Function of fermented soybean extractalso revealed the tendency to suppress (P<0.07)
cytotoxicity caused by dichromate.
Lipid Peroxidation
As shown in Fig. 5, the treatment of hepatocytes with
1mM dichromate alone for 8h revealed a significant
increase (P<0.05) in MDA formation of 1.7nmolmg
1
protein, when compared with MDA formation of
0.3nmolmg
1 protein for the control cells without any
treatment. However, when the cells were treated with BF
at concentrations of 5 or 10ml/ml combined with
dichromate, significant (50% or more) inhibitions
(P<0.05) of MDA formation was observed, indicating
that BF treatment exhibited a protective effect against
cytotoxity caused by dichromate. No increase in MDA
formation occurred among cells treated with BF alone in
the test range of 1.3–10mlml
1.
Discussion
DCA, a secondary bile acid, is highly toxic and causes
cholestatic hepatopathy in experimental animals (21).
When the concentration of bile acids exceeds the binding
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Figure 2. Effects of oral BF administration on serum AST activity in
rats with D-galactosamine (GMN)-induced hepatic disorders. The
control group (open square) was given MF powdery feed only for
3 weeks, while the BF group (filled circle) was given MF powdery feed
containing 5% BF. On the first day of the fourth week of feeding
period, the rats of both groups were injected intraperitoneally with
GMN solution (500mg/kg body wt). Serum AST was measured on days
1, 2, 3 and 6 after GMN injection. Values indicate meanSD (n=7).
*P<0.05 against the respective control values. BF, Biofermentics
TM
(lactic acid bacteria-fermented soybean extract).
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Figure 3. Effects of BF treatment on dichromate-induced cytotoxicity in
primary cultures of rat hepatocytes. Hepatocytes were treated with BF
alone (open square) or with a combination of BF and dichromate
(1mM) (filled square) for 8h at 37C in SGM. The effect of BF was
evaluated as a percent of decreased LDH leakage against the total LDH
from control hepatocytes without any treatment. Bars indicate
meanSD (n=4). P<0.05 of superscript a as compared with values
of superscript b and c. BF, Biofermentics
TM (lactic acid bacteria-
fermented soybean extract). LDH, lactate dehydrogenase.
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Figure 4. Effects of BF treatment on dichromate-induced cytotoxicity in
primary cultures of rat nephrocytes. Nephrocytes were treated with BF
alone (open square) or with a combination of BF and dichromate
(1mM) (filled square) for 8h at 37C in SGM. The effect of BF was
evaluated by the percent decrease of LDH leakage in the nephrocytes
treated by BF and dichromate. Bars indicate meanSD (n=4).
P<0.05 of superscript a as compared with the value of superscript
c. P<0.07 of superscript b as compared with the value of superscript
a. BF, Biofermentics
TM (lactic acid bacteria-fermented soybean extract).
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Figure 5. Effects of BF treatment on dichromate-induced lipid
peroxidation. Hepatocytes were treated with BF alone (open square)
or with dichromate (1mM) and BF(filled square) for 8h at 37Ci n
salt-glucose medium. The effect of BF treatment was estimated by
monitoring decreased malondialdehyde (MDA) formation through lipid
peroxidation. Values indicate meanSD (n=4). P<0.05 of super-
script a as compared with the value of superscript c. P<0.05 of
superscript b as compared with the value of superscript a. BF,
Biofermentics
TM (lactic acid bacteria-fermented soybean extract).
eCAM 2009;6(3) 361capacity of binding proteins located in the cytosol of the
hepatocytes, bile acids induce apoptosis and necrosis by
damaging mitochondria (22). Hydrophobic bile acids
induce alterations in membrane fluidity associated with
impairment of mitochondrial respiration and depolariza-
tion. In this study, it was considered that the suppression
of bile acid concentration in hepatocytes was one of the
mechanisms for BF to reduce the damage to hepatocytes.
We found that the BF administered group tended to
show lower values of total bile acid concentration in
serum than control groups (Table 2). As a reason why
the concentration of bile acid in hepatocytes was
suppressed by BF, it is suspected that the absorption of
DCA by intestinal mucosa was decreased by inhibiting
the conjugation of bile acids with amino acids and by
lowering the active transportation activity of bile acids in
intestinal mucosa, though this supposition is unclear and
requires further study.
In a model of human viral hepatitis, GMN inhibits the
protein and the nucleic acid synthesis of hepatocytes
(23,24). It has been reported that various kinds of dietary
amino acids, such as L-serine, L-aspargine, L-histidine,
L-lysine, L-tyrosine, L-glycine and L-glutamine, were
effective in protecting rats from GMN-induced injury
(25). Moreover, the effects of oligosaccharides and
dietary fiber have been shown to prevent GMN-induced
hepatic injury (26). Therefore, we believe that amino
acids and oligosaccharides, ingredients of BF originating
from soymilk, are partly attributable to protection
against GMN-induced hepatic disorders.
Hexavalent chromium is reduced to stable form of
trivalent chromium in hepatic and renal cells (15). It has
been considered that the active oxygen (hydroxyl radical
OH) produced in these cells causes damage to the cell
membrane and DNA through lipid peroxidation, which
leads to leakage of LDH in the cell. It has also been
reported that aglycones from saponin or isofravone
glycosides, both ingredients of soymilk, are released by
b-glucosidase of lactic acid bacteria (5,6). As such, we
suspect that the anti-oxidative powers of BF were
conserved in the process of fermentation by the mixed
culture of the lactic acid bacteria and yeast in this study.
Therefore, the anti-oxidative effect of BF prevented lipid
peroxidation by chromium, and we believe that the power
of BF as an anti-oxidant is similar to that of a lot of
other anti-oxidation substances such as catechin, chloro-
genic acid, vitamin E and melatonin, as previously tested
(14,15,19). There have been many reports about the
therapeutic benefits of plant herbs and fruits, notably on
their anti-oxidant properties (27–29). Accordingly, taking
fermented soybean extract, such as the BF used in this
article, as an anti-oxidant every day may contribute to
better overall health of humans
There have been reports about the functionality of the
soybean as fermented by different micro-organisms
(30,31). Moreover, it has been postulated that products
of fermentation with two or more bacteria, are consider-
ably more complicated than those with a single kind of
bacterium (32,33). Although we did not examine the
fermentation products of each bacterium used for the
production of BF in this experiment, further study is
needed for both single and co-cultivation to isolate the
specific fermentation products responsible for the anti-
oxidative effects of BF.
In conclusion, this study suggests that BF may be applied
to an improvement of hepatic and renal disorders, BF may
also possess other health benefits in humans.
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